...
首页> 外文期刊>Molecular Therapy - Methods & Clinical Development >One-Step Fabrication of Bone Morphogenetic Protein-2 Gene-Activated Porous Poly-L-Lactide Scaffold for Bone Induction
【24h】

One-Step Fabrication of Bone Morphogenetic Protein-2 Gene-Activated Porous Poly-L-Lactide Scaffold for Bone Induction

机译:骨形态发生蛋白-2基因活化多孔多孔聚乙酯支架骨诱导的一步制造

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Bone morphogenetic protein 2 (BMP2) is an efficacious inducer for the osteogenesis of mesenchymal stem cells (MSCs). Conventional applications of BMP2 have involved either the direct incorporation of BMP2 protein or ex?vivo BMP2 gene transfer into stem cells prior to their transplantation. These approaches are able to promote bone formation to some extent; however, they are hampered by either the lack of stability and sustainability of BMP2 protein or the time-consuming and cost-prohibitive in?vitro cell culture procedure. To overcome these limitations, we have developed a gene-activated poly-L-lactide acid (PLLA) scaffold with the encapsulation of recombinant adeno-associated viral (AAV) vector encoding a full-length cDNA of human BMP2 using an ice-based microparticle porogenization method that was recently developed. Results showed continuous release of AAV particles from the micropores of scaffolds for up to 1?week, subsequently transducing embedded human MSCs and producing functional BMP2. MSCs within scaffolds underwent efficacious osteogenesis, on the basis of osteoinductive gene expression and osteogenic differentiation, which resulted in robust new bone formation in?vivo at 4?weeks. These findings show the potential of the technology toward developing clinical applications of a rapid, cost-effective, and potentially point-of-care approach for the repair of bone defects.
机译:骨形态发生蛋白2(BMP2)是用于间充质干细胞(MSCs)的骨质发生的有效诱导剂。 BMP2的常规应用涉及在移植之前将BMP2蛋白或前BMP2基因转移到干细胞中的直接掺入。这些方法能够在一定程度上促进骨骼形成;然而,它们因缺乏BMP2蛋白的稳定性和可持续性而受到阻碍,或者在体外细胞培养程序中耗时和成本抑制的耗时和持久性。为了克服这些限制,我们开发了一种基因 - 活化的聚-L-丙交酯(PLLA)支架,其包裹使用冰基微粒编码人BMP2的全长cDNA的重组腺相关病毒(AAV)载体的包封最近开发的方法。结果表明,从支架的微孔中连续释放到高达1?周,随后转换嵌入式人体MSC和产生功能性BMP2。在骨诱导基因表达和骨质发生分化的基础上,支架内的MSC在骨诱导基因表达和骨形成的基础上进行了有效的成骨,这导致4?周的体内具有稳健的新骨形成。这些调查结果表明了该技术促进了发展快速,经济效益和潜在的护理方法的临床应用,以便修复骨缺损。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号